INSM vs. HCM, AXSM, CRNX, PBH, PRGO, ALKS, RARE, BHVN, SMMT, and NUVL
Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include HUTCHMED (HCM), Axsome Therapeutics (AXSM), Crinetics Pharmaceuticals (CRNX), Prestige Consumer Healthcare (PBH), Perrigo (PRGO), Alkermes (ALKS), Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), Summit Therapeutics (SMMT), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical preparations" industry.
Insmed (NASDAQ:INSM) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
HUTCHMED has a net margin of 0.00% compared to Insmed's net margin of -236.74%.
In the previous week, Insmed had 24 more articles in the media than HUTCHMED. MarketBeat recorded 32 mentions for Insmed and 8 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.84 beat Insmed's score of 0.47 indicating that HUTCHMED is being referred to more favorably in the news media.
Insmed presently has a consensus target price of $44.71, suggesting a potential upside of 80.52%. HUTCHMED has a consensus target price of $29.70, suggesting a potential upside of 47.25%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Insmed is more favorable than HUTCHMED.
Insmed received 193 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.60% of users gave HUTCHMED an outperform vote while only 64.79% of users gave Insmed an outperform vote.
HUTCHMED has higher revenue and earnings than Insmed.
8.8% of HUTCHMED shares are owned by institutional investors. 4.6% of Insmed shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Insmed has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
Summary
Insmed beats HUTCHMED on 8 of the 15 factors compared between the two stocks.
Get Insmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
